Rates Increase Abroad Due to High Demand
Asia, Latin American, and Eastern Europe are increasingly attractive geographies in which to conduct clinical research.
Asia, Latin American, and Eastern Europe are increasingly attractive geographies in which to conduct clinical research. The data in GrantPlan® shows that overhead rates in many countries are increasing, as illustrated by China and India. According to www.ClinicalTrials.gov, GrantPlan subscribers conduct over 76 percent of all clinical trials.
Drug development professionals already know that successful investigators and sites often seek to command a premium in any discussion over clinical trial agreement negotiations. Similarly, when multiple studies in the same indication are looking to enlist investigators, individual sites are often in a stronger position to command a price premium. We see much the same phenomenon at work in geographies newer to clinical research. They offer large naïve patient pools, well trained physicians, and potentially lower costs.
Average institutional overhead rates in China and India.
For instance, recent data shows that China and India are experiencing sustained growth in the number of clinical sites involved in commercial clinical trial activity. Unlike in the United States, the vast majority of clinical research in China and India is done in hospitals, rather than private practice. The demand for clinical research services is growing in the institutions, while the supply is clearly limited.
Many of these institutions in China and India are putting in substantial effort to better understand their clinical trials' indirect costs. These are all the costs that are necessary to sustain the infrastructure for the conduct of clinical research, but which cannot be directly charged to any specific project. Supply and demand also helps to explain the increase in overhead rates. These institutions are in demand. Institutions can charge these rates because someone will pay them.
—TTC for more information, contact help@ttc-llc.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
